Wang Y, et al. - In this retrospective analysis of 11 Ewing’s sarcoma patients (ES; with mean age 18 years) who poorly responded to two cycles of chemotherapy (vincristine, doxorubicin, and cyclophosphamide), the efficacy and safety of apatinib, a specific vascular endothelial growth factor receptor 2 inhibitor, was tested using the Response Evaluation Criteria in Solid Tumors 1.1. Survival was assessed in relation to apatinib 500 mg (or 250 mg) given daily. Sixteen months of median follow-up was performed. The observed 12-month overall survival and progression-free survival rates were 90% and 72%, respectively, with partial response seen in 4 patients and stable disease in 4, with objective response rate of 40%. Hand–foot skin reaction, oral ulcers, and gastrointestinal discomfort were most commonly experienced adverse events. Overall, apatinib could afford second- or first-line treatment option for ES patients, particularly in chemoresistant cases.